Listed

Sunshine Biopharma Inc.: Form 10-K for the period ended Dec 31, 2013

Filed with the SEC on Mar 19, 2014 and accepted by EDGAR at Mar 19, 2014, 16:38 ET.

Share

Sections

The sections of this filing are being extracted from EDGAR and appear here in about a minute. Meanwhile, read the original on sec.gov. The main document on sec.gov.

Figures reported in this filing

Standardized line items from the XBRL in this filing, for the period ended 2013-12-31. Comparative periods it repeats are left out.

Figures reported in this filing
Line itemPeriodValueXBRL concept
Revenue12 months2013-01-01 to 2013-12-31$0us-gaap:SalesRevenueGoodsNet
Research and development12 months2013-01-01 to 2013-12-31$137.4kus-gaap:ResearchAndDevelopmentExpense
Operating income12 months2013-01-01 to 2013-12-31−$1.9mus-gaap:OperatingIncomeLoss
Interest expense12 months2013-01-01 to 2013-12-31$6.5kus-gaap:InterestExpense
Net income12 months2013-01-01 to 2013-12-31−$2.5mus-gaap:NetIncomeLoss
Basic EPS12 months2013-01-01 to 2013-12-31−$0.04us-gaap:EarningsPerShareBasic
Operating cash flow12 months2013-01-01 to 2013-12-31−$564.4kus-gaap:NetCashProvidedByUsedInOperatingActivities
Cash and equivalentsAt period end2013-12-31$31.2kus-gaap:CashAndCashEquivalentsAtCarryingValue
Current assetsAt period end2013-12-31$31.2kus-gaap:AssetsCurrent
Total assetsAt period end2013-12-31$31.2kus-gaap:Assets
Total liabilitiesAt period end2013-12-31$39.0kus-gaap:Liabilities
Shareholders' equityAt period end2013-12-31−$7.7kus-gaap:StockholdersEquity

Source: SEC EDGAR, the filing index for accession 0001354488-14-001275. Last ingested by Listed: Nov 14, 2026, 19:46 ET. Listed shows no prices and gives no investment advice.